<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="in a credit line to the data. Abstract Abstract COVID-19" exact="disease" post="with a high rate of contagious and highly nonspecific"/>
 <result pre="high rate of contagious and highly nonspecific symptoms, is an" exact="infectious disease" post="caused by a newly discovered coronavirus. Most people who"/>
 <result pre="rate of contagious and highly nonspecific symptoms, is an infectious" exact="disease" post="caused by a newly discovered coronavirus. Most people who"/>
 <result pre="with COVID-19 will experience mild to moderate symptoms such as" exact="respiratory" post="symptoms, cough, dyspnea, fever, and viral pneumonia and recover"/>
 <result pre="moderate symptoms such as respiratory symptoms, cough, dyspnea, fever, and" exact="viral pneumonia" post="and recover without any special cure. However, some others"/>
 <result pre="symptoms such as respiratory symptoms, cough, dyspnea, fever, and viral" exact="pneumonia" post="and recover without any special cure. However, some others"/>
 <result pre="paper is to review typical and ongoing treatments for coronavirus" exact="disease" post="including home remedies, herbal medicine, chemical drugs, plasma therapy,"/>
 <result pre="coronavirus in the subgenus Sarbecovirus [2]. The WHO named the" exact="disease" post="as COVID-19 [3] and it spread all over the"/>
 <result pre="species, including humans [4]. The virus that causes the COVID-19" exact="infection" post="belongs to the Î² coronaviruses family. Since the beginning"/>
 <result pre="century, three coronaviruses crossed the species barrier and causes deadly" exact="pneumonia" post="in humans: severe acute respiratory syndrome coronavirus (SARS-CoV) [5],"/>
 <result pre="the species barrier and causes deadly pneumonia in humans: severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) [5], Middle-East respiratory syndrome coronavirus"/>
 <result pre="species barrier and causes deadly pneumonia in humans: severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) [5], Middle-East respiratory syndrome coronavirus [6],"/>
 <result pre="barrier and causes deadly pneumonia in humans: severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) [5], Middle-East respiratory syndrome coronavirus [6], and"/>
 <result pre="in humans: severe acute respiratory syndrome coronavirus (SARS-CoV) [5], Middle-East" exact="respiratory" post="syndrome coronavirus [6], and SARS-CoV-2 [7]. Unlike previous coronaviruses"/>
 <result pre="humans: severe acute respiratory syndrome coronavirus (SARS-CoV) [5], Middle-East respiratory" exact="syndrome" post="coronavirus [6], and SARS-CoV-2 [7]. Unlike previous coronaviruses that"/>
 <result pre="coronaviruses that caused large-scale epidemics such as the Middle East" exact="Respiratory" post="Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS), the"/>
 <result pre="that caused large-scale epidemics such as the Middle East Respiratory" exact="Syndrome" post="(MERS) and Severe Acute Respiratory Syndrome (SARS), the transmission"/>
 <result pre="epidemics such as the Middle East Respiratory Syndrome (MERS) and" exact="Severe" post="Acute Respiratory Syndrome (SARS), the transmission rate for COVID-19"/>
 <result pre="such as the Middle East Respiratory Syndrome (MERS) and Severe" exact="Acute" post="Respiratory Syndrome (SARS), the transmission rate for COVID-19 is"/>
 <result pre="as the Middle East Respiratory Syndrome (MERS) and Severe Acute" exact="Respiratory" post="Syndrome (SARS), the transmission rate for COVID-19 is much"/>
 <result pre="the Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory" exact="Syndrome" post="(SARS), the transmission rate for COVID-19 is much higher"/>
 <result pre="high rate of contagious and highly nonspecific symptoms of this" exact="disease" post="such as respiratory symptoms, cough, dyspnea, fever, and viral"/>
 <result pre="contagious and highly nonspecific symptoms of this disease such as" exact="respiratory" post="symptoms, cough, dyspnea, fever, and viral pneumonia [7], the"/>
 <result pre="this disease such as respiratory symptoms, cough, dyspnea, fever, and" exact="viral pneumonia" post="[7], the establishment of precise and fast diagnostic tests"/>
 <result pre="disease such as respiratory symptoms, cough, dyspnea, fever, and viral" exact="pneumonia" post="[7], the establishment of precise and fast diagnostic tests"/>
 <result pre="verify suspected cases, screen patients, and conduct virus surveillance. The" exact="disease" post="is typically confirmed by reverse-transcription polymerase chain reaction (RT-PCR)"/>
 <result pre="in developing medicines or remedies for the treatment of COVID-19" exact="disease" post="to help researchers around the world to find advantage"/>
 <result pre="they are rapidly growing up [12]. For example, fatal severe" exact="diarrhea" post="syndrome in pigs, associated with an HKU2-related coronavirus of"/>
 <result pre="are rapidly growing up [12]. For example, fatal severe diarrhea" exact="syndrome" post="in pigs, associated with an HKU2-related coronavirus of bat"/>
 <result pre="[12]. SARS-CoV-2 is a virus from coronaviruses family which causes" exact="infection" post="in humans; SARS-CoV, MERS-CoV, and SARS-CoV-2 can cause acute"/>
 <result pre="causes infection in humans; SARS-CoV, MERS-CoV, and SARS-CoV-2 can cause" exact="acute" post="disease, while NL63, HKU1, OC43, and 229E cause mild"/>
 <result pre="and 229E cause mild symptoms [16]. The first time that" exact="Severe" post="acute respiratory syndrome (SARS) coronavirus (SARS-CoV) appeared, it was"/>
 <result pre="229E cause mild symptoms [16]. The first time that Severe" exact="acute" post="respiratory syndrome (SARS) coronavirus (SARS-CoV) appeared, it was in"/>
 <result pre="cause mild symptoms [16]. The first time that Severe acute" exact="respiratory" post="syndrome (SARS) coronavirus (SARS-CoV) appeared, it was in Guangdong,"/>
 <result pre="mild symptoms [16]. The first time that Severe acute respiratory" exact="syndrome" post="(SARS) coronavirus (SARS-CoV) appeared, it was in Guangdong, southern"/>
 <result pre="November 2002 and the first time when the Middle East" exact="respiratory" post="syndrome (MERS) coronavirus (MERS-CoV) emerged, it was in 2012"/>
 <result pre="2002 and the first time when the Middle East respiratory" exact="syndrome" post="(MERS) coronavirus (MERS-CoV) emerged, it was in 2012 in"/>
 <result pre="MERS-CoV outbreak in September 2012, caused 2494 confirmed cases of" exact="infection" post="and 858 mortalities, including 38 fatalities in South Korea"/>
 <result pre="[19, 20]. In late December 2019, many infected patients with" exact="viral pneumonia" post="were reported, but the point was that all of"/>
 <result pre="20]. In late December 2019, many infected patients with viral" exact="pneumonia" post="were reported, but the point was that all of"/>
 <result pre="GMT. At present, available data shows that 2019-nCoV spread the" exact="infection" post="to the human population from a bat source, but"/>
 <result pre="species are associated with this virus and acting as an" exact="intermediate" post="host between humans and bat or not. Full-genome sequencing"/>
 <result pre="of the COVID-19- infected cases will face mild to moderate" exact="respiratory" post="illness and they will recover without requiring special therapies."/>
 <result pre="therapies. Elders and those with underlying medical problems such as" exact="cardiovascular disease," post="chronic respiratory disease, diabetes, and cancer are more in"/>
 <result pre="and those with underlying medical problems such as cardiovascular disease," exact="chronic" post="respiratory disease, diabetes, and cancer are more in danger"/>
 <result pre="those with underlying medical problems such as cardiovascular disease, chronic" exact="respiratory" post="disease, diabetes, and cancer are more in danger to"/>
 <result pre="problems such as cardiovascular disease, chronic respiratory disease, diabetes, and" exact="cancer" post="are more in danger to develop serious illnesses. At"/>
 <result pre="against SARS-CoV-2 Most over-the-counter treatments only cure the symptoms of" exact="viral" post="infections but they donâ€™t help the immune system to"/>
 <result pre="SARS-CoV-2 Most over-the-counter treatments only cure the symptoms of viral" exact="infections" post="but they donâ€™t help the immune system to fight"/>
 <result pre="prevention of SARS-Cov-2 for Stress reduction, self-care, sore throats, and" exact="respiratory" post="congestion and sinuses are given. Stress Reduction With the"/>
 <result pre="sinuses are given. Stress Reduction With the outbreak of coronavirus" exact="disease" post="(COVID-19) in 2020, and with increasing numbers of confirmed"/>
 <result pre="and the public have been experiencing psychological problems, including stress," exact="anxiety" post="and depression [26, 27]. On January 26, 2020, the"/>
 <result pre="public have been experiencing psychological problems, including stress, anxiety and" exact="depression" post="[26, 27]. On January 26, 2020, the National Health"/>
 <result pre="Also, the WHO recommends Dancing, skipping rope, some training for" exact="muscle" post="strength and online exercise classes for the reduction of"/>
 <result pre="of stress and boosting the immune system [25]. Self-Care When" exact="upper" post="respiratory infections occur, rest and plentiful hydration are helpful."/>
 <result pre="stress and boosting the immune system [25]. Self-Care When upper" exact="respiratory" post="infections occur, rest and plentiful hydration are helpful. At"/>
 <result pre="and boosting the immune system [25]. Self-Care When upper respiratory" exact="infections" post="occur, rest and plentiful hydration are helpful. At this"/>
 <result pre="are helpful for hydration and decreasing the symptoms of the" exact="infectious" post="[29]. Sore Throats The first step in battling bacterial"/>
 <result pre="the infectious [29]. Sore Throats The first step in battling" exact="bacterial" post="throat infections is saltwater gargles, which is perfect for"/>
 <result pre="[29]. Sore Throats The first step in battling bacterial throat" exact="infections" post="is saltwater gargles, which is perfect for loosening mucus"/>
 <result pre="the use of saline or vinegar to kill the coronavirus." exact="Respiratory" post="Congestion and Sinuses For respiratory congestion, useful things are"/>
 <result pre="vinegar to kill the coronavirus. Respiratory Congestion and Sinuses For" exact="respiratory" post="congestion, useful things are vaporizers, humidifier, or steam inhalers,"/>
 <result pre="prolonged studies. Herein, we will mention various drugs used for" exact="viral" post="disease treatment which is also showing inhibitory effect, etc."/>
 <result pre="studies. Herein, we will mention various drugs used for viral" exact="disease" post="treatment which is also showing inhibitory effect, etc. in"/>
 <result pre="an active form by becoming phosphoribosylated (favipiravir-RTP) and will recognize" exact="viral" post="RNA polymerase, inhibiting its activity [43]. So, Favipiravir may"/>
 <result pre="SARS-CoV-2; researches showed that Favipiravir independently associates with more active" exact="viral" post="clearance and higher improvement rates in the chest imaging"/>
 <result pre="more active viral clearance and higher improvement rates in the" exact="chest" post="imaging and has a positive impact on treating patients"/>
 <result pre="and their test results were appeared negative after a relatively" exact="short" post="time. Also, the symptoms of pneumonia were significantly reduced."/>
 <result pre="negative after a relatively short time. Also, the symptoms of" exact="pneumonia" post="were significantly reduced. In another study in Wuhan, showed"/>
 <result pre="Hydroxychloroquine Chloroquine (CQ) is a drug that widely used against" exact="malaria" post="and in 2006 was observed this drug has an"/>
 <result pre="pH higher than what is required for virus/cell fusion, the" exact="infection" post="is blocked. This interferes with glycoproteins of cellular receptors"/>
 <result pre="[47]. Therefore, Chloroquine can inhibit a pre-entry step of the" exact="viral" post="cycle via interfering with the binding of viral particles"/>
 <result pre="of the viral cycle via interfering with the binding of" exact="viral" post="particles to their cellular cell surface receptor [48]. In"/>
 <result pre="Vero E6 cells infected by SARS-CoV-2 at a multiplicity of" exact="infection" post="(MOI) of 0.05, Chloroquine was highly effective in decreasing"/>
 <result pre="infection (MOI) of 0.05, Chloroquine was highly effective in decreasing" exact="viral" post="replication and it can block SARS-CoV-2 infection at low"/>
 <result pre="effective in decreasing viral replication and it can block SARS-CoV-2" exact="infection" post="at low concentration (half-maximal effective concentration (EC50) of 1.13â€‰Î¼M"/>
 <result pre="indicated that Chloroquine can inhibit in-vitro replication of HCoV-229E in" exact="epithelial" post="lung cell cultures [50, 51] and also can be"/>
 <result pre="[50, 51] and also can be effective against Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) in-vitro [52]. Hydroxychloroquine (HCQ) with a"/>
 <result pre="51] and also can be effective against Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) in-vitro [52]. Hydroxychloroquine (HCQ) with a very"/>
 <result pre="of the disease-modifying antirheumatic drugs that use for healing many" exact="rheumatic" post="diseases and also demonstrate a strong immunomodulatory capacity which"/>
 <result pre="[47]. They can also inhibit nucleic acid replication, glycosylation of" exact="viral" post="proteins, virus assembly, new virus particle transport, virus release,"/>
 <result pre="have important implications for patient care and public health. â€˜A" exact="total" post="of 1542 patients were randomized to Hydroxychloroquine and compared"/>
 <result pre="usual care alone. There was no significant difference in the" exact="primary" post="endpoint of 28-day mortality (25.7% Hydroxychloroquine vs. 23.5% usual"/>
 <result pre="nucleotide analog of adenosine 5-monophosphate - with antiviral activity against" exact="hepatitis" post="B virus, HIV [55], filoviruses, paramyxoviruses, and pathogenic coronaviruses,"/>
 <result pre="and MERS, the combination of ribavirin and IFN-Î², decreases the" exact="viral" post="replication and disease severity in animal models [64]. Due"/>
 <result pre="combination of ribavirin and IFN-Î², decreases the viral replication and" exact="disease" post="severity in animal models [64]. Due to unfavorable reactions,"/>
 <result pre="anti-hypertensive agent that is presently suggested for the regulation of" exact="high blood pressure," post="particularly those cases that are prone to diabetic nephropathies."/>
 <result pre="of AngII. Then plasma renin activity increases due to the" exact="absence of" post="AngII and some biochemical events occur such as AngI"/>
 <result pre="can prevent or control persistent fibrotic diseases such as cardiac" exact="hypertrophy" post="and asthma in addition to hypertension. Moreover, apart from"/>
 <result pre="or control persistent fibrotic diseases such as cardiac hypertrophy and" exact="asthma" post="in addition to hypertension. Moreover, apart from direct anti-hypertensive"/>
 <result pre="diagnosed hypertensive patients which is suggestive for applying losartan for" exact="thrombosis" post="and atherosclerosis as well. Other lateral functions of losartan"/>
 <result pre="patients which is suggestive for applying losartan for thrombosis and" exact="atherosclerosis" post="as well. Other lateral functions of losartan considered to"/>
 <result pre="and significantly regulating IFN-Î³, IL-6, IL-17F, and IL-22 cytokines in" exact="peripheral" post="blood mononuclear cells (PBMCs) of rheumatoid arthritis patients. Finally,"/>
 <result pre="and IL-22 cytokines in peripheral blood mononuclear cells (PBMCs) of" exact="rheumatoid arthritis" post="patients. Finally, an earlier hypothesis illustrated that losartan as"/>
 <result pre="IL-22 cytokines in peripheral blood mononuclear cells (PBMCs) of rheumatoid" exact="arthritis" post="patients. Finally, an earlier hypothesis illustrated that losartan as"/>
 <result pre="could be useful for patients infected by COVID-19 who experience" exact="pneumonia" post="[66]. The role of the Renin-Angiotensin-Aldosterone System (RAAS) in"/>
 <result pre="[66]. The role of the Renin-Angiotensin-Aldosterone System (RAAS) in COVID-19" exact="infection" post="is a hot topic of discussion. RAAS inhibitors, such"/>
 <result pre="II receptor blockers (ARBs), which are used to treatment of" exact="cardiovascular" post="diseases, have been resulted in increased cell surface levels"/>
 <result pre="II-mediated vasoconstriction. Besides, aldosterone inhibitors (e.g., spironolactone, eplerenone, amiloride) control" exact="vascular" post="tone by affecting sodium channels for sodium reabsorption in"/>
 <result pre="II (IFN-Î³), and III, all of which play roles against" exact="viral" post="infections [69]. Type-I interferon (IFN-I) activates intracellular pathogen defense"/>
 <result pre="(IFN-Î³), and III, all of which play roles against viral" exact="infections" post="[69]. Type-I interferon (IFN-I) activates intracellular pathogen defense and"/>
 <result pre="genes (STING) can control transcription of many inflammatory mediators, including" exact="type I" post="and type III interferons [70]. Reports showed that the"/>
 <result pre="control transcription of many inflammatory mediators, including type I and" exact="type III" post="interferons [70]. Reports showed that the administration of moxifloxacin,"/>
 <result pre="immune cells to IFNs during CoV infections. Differences in the" exact="primary" post="immune responses due to the interferon -depending on the"/>
 <result pre="that their data about the identified gene expression signatures of" exact="viral" post="invasion and type I interferon (IFN-I) responses is the"/>
 <result pre="about the identified gene expression signatures of viral invasion and" exact="type I" post="interferon (IFN-I) responses is the key characterizing factor for"/>
 <result pre="the key characterizing factor for the diagnosis of the COVID-19" exact="infection" post="stage in humans. The relationship between viral load/IFN levels"/>
 <result pre="of the COVID-19 infection stage in humans. The relationship between" exact="viral" post="load/IFN levels and disease severity in COVID-19 infection marked"/>
 <result pre="stage in humans. The relationship between viral load/IFN levels and" exact="disease" post="severity in COVID-19 infection marked the key difference in"/>
 <result pre="relationship between viral load/IFN levels and disease severity in COVID-19" exact="infection" post="marked the key difference in the pathogenesis of this"/>
 <result pre="of this new from the previous coronavirus such as SARS-CoV" exact="infections" post="[72]. Lopinavir â€&quot; Ritonavir Three anti-HIV drugs, ritonavir, lopinavir,"/>
 <result pre="lopinavir, and darunavir, might have a therapeutic impact on coronavirus" exact="disease" post="2019 (COVID-19). It is implied that the therapeutic effect"/>
 <result pre="may be largely due to its inhibitory effect on PLVP(papain-like" exact="viral" post="protease) [73]. Lopinavir is metabolized by cytochrome P4503A (CYP3A)"/>
 <result pre="combination as a second-line drug for the treatment of HIV-1" exact="infection" post="in children and grown-ups through the fewer side effects."/>
 <result pre="lopinavir/ritonavir against SARS-CoV and MERS-CoV infections. The reduction of steroid" exact="consumption" post="and nosocomial infections was seen in patients initially treated"/>
 <result pre="SARS-CoV and MERS-CoV infections. The reduction of steroid consumption and" exact="nosocomial infections" post="was seen in patients initially treated with lopinavir/ritonavir. Also,"/>
 <result pre="and MERS-CoV infections. The reduction of steroid consumption and nosocomial" exact="infections" post="was seen in patients initially treated with lopinavir/ritonavir. Also,"/>
 <result pre="in patients initially treated with lopinavir/ritonavir. Also, results indicate decreasing" exact="viral" post="load and enhancing peripheral lymphocyte count. Findings from in"/>
 <result pre="with lopinavir/ritonavir. Also, results indicate decreasing viral load and enhancing" exact="peripheral" post="lymphocyte count. Findings from in vitro and clinical studies,"/>
 <result pre="study. A new report showed that the average span of" exact="viral" post="shedding in COVID-19 was 20â€‰days in patients with severe"/>
 <result pre="lopinavir-ritonavir treatment did not significantly improve clinical development or reduce-throat" exact="viral" post="RNA detectability in patients with serious COVID-19 [77]. Actemra"/>
 <result pre="salt concentration in the blood, so it could contribute to" exact="pneumonia" post="seen in severe cases.[78]. Tocilizumab is an efficient remedy"/>
 <result pre="symptoms, which provided a new therapeutic approach for this fatal" exact="infectious disease." post="By using this drug after a few days, the"/>
 <result pre="cytokine release syndrome), has been approved in patients with COVID-19" exact="pneumonia" post="and raised IL-6 in China (ChiCTR2000029765) [80]. Also, disruption"/>
 <result pre="beneficial effects in treating Chinese COVID-19 patients with cytokine storm" exact="syndrome" post="[81]. Studies have shown that IL-6 levels significantly associated"/>
 <result pre="D has many mechanisms that reduce the risk of microbial" exact="infection" post="and death. Vitamin D with enhance cellular innate immunity"/>
 <result pre="and nonenveloped viruses, and fungi. It is known that COVID-19" exact="infection" post="is associated with the increasing production of pro-inflammatory cytokines,"/>
 <result pre="production of pro-inflammatory cytokines, C-reactive protein, increase risk of pneumonia," exact="acute" post="respiratory distress syndrome, and heart failure. (Evidence that Vitamin"/>
 <result pre="of pro-inflammatory cytokines, C-reactive protein, increase risk of pneumonia, acute" exact="respiratory" post="distress syndrome, and heart failure. (Evidence that Vitamin D"/>
 <result pre="C-reactive protein, increase risk of pneumonia, acute respiratory distress syndrome," exact="and heart" post="failure. (Evidence that Vitamin D Supplementation Could Reduce the"/>
 <result pre="protein, increase risk of pneumonia, acute respiratory distress syndrome, and" exact="heart" post="failure. (Evidence that Vitamin D Supplementation Could Reduce the"/>
 <result pre="D Supplementation Could Reduce the Risk of Influenza and COVID-19" exact="Infections" post="and deaths). Vitamin D also deregulates the inflammatory response,"/>
 <result pre="evidence for that vitamin D can prevent or treat COVID-19" exact="infection" post="and should be further studied before it is recommended"/>
 <result pre="(RdRp) that is a core enzyme in their RNA-synthesizing machinery." exact="Increased" post="Zn2+ levels directly inhibit isolated RdRp complexes and purified."/>
 <result pre="RdRp complexes and purified. Zinc supplementation can benefit patients with" exact="lower" post="respiratory tract infections such as COVID-19. Because of its"/>
 <result pre="complexes and purified. Zinc supplementation can benefit patients with lower" exact="respiratory" post="tract infections such as COVID-19. Because of its role"/>
 <result pre="purified. Zinc supplementation can benefit patients with lower respiratory tract" exact="infections" post="such as COVID-19. Because of its role in immune"/>
 <result pre="labetalol -Antiarrhythmics QT-prolonging agents Digoxin Additionally, itâ€™s noted that Hydroxychloroquine" exact="consumption" post="is better than chloroquine (during long-term use) due to"/>
 <result pre="[89â€&quot;91]. In 2014, WHO suggested the use of convalescent plasma" exact="acquired" post="from Ebola virus-infected cases who had recovered as an"/>
 <result pre="use of convalescent plasma in the remedy of Middle East" exact="respiratory" post="syndrome coronavirus was appointed [93]. In a study, Hung"/>
 <result pre="of convalescent plasma in the remedy of Middle East respiratory" exact="syndrome" post="coronavirus was appointed [93]. In a study, Hung and"/>
 <result pre="[94]. Besides, in a subgroup analysis, after convalescent plasma therapy" exact="viral" post="load was lower on days 3, 5, and 7"/>
 <result pre="a subgroup analysis, after convalescent plasma therapy viral load was" exact="lower" post="on days 3, 5, and 7 after intensive care"/>
 <result pre="the effects of this antibody were not only blocking new" exact="infection" post="and viral clearance but also involves fast clearance of"/>
 <result pre="of this antibody were not only blocking new infection and" exact="viral" post="clearance but also involves fast clearance of infected cells"/>
 <result pre="In the first week of infection, Viraemia peaks occur in" exact="viral" post="infections. By days 10â€&quot;14 and through virus clearance, the"/>
 <result pre="10â€&quot;14 and through virus clearance, the patient usually arises a" exact="primary" post="immune response [91]. So, theoretically, it looks like that"/>
 <result pre="be more useful to administer the convalescent plasma at the" exact="primary" post="stage of disease [98]. However, other therapies might affect"/>
 <result pre="to administer the convalescent plasma at the primary stage of" exact="disease" post="[98]. However, other therapies might affect the connection between"/>
 <result pre="immunoglobulin, and steroids [99]. WHO recommended the main focus on" exact="infection" post="prevention, infected detection and monitoring, and supportive treatment for"/>
 <result pre="indicates that convalescent plasma from patients who have recovered from" exact="viral" post="infections can be applied as a therapy without the"/>
 <result pre="that convalescent plasma from patients who have recovered from viral" exact="infections" post="can be applied as a therapy without the occurrence"/>
 <result pre="convalescent plasma treatment showed better oxygenation and less inflammation and" exact="viral" post="load [102]. In one study Chenguang Shen et al.,"/>
 <result pre="of plasma were 5 patients who were recovered from SARS-CoV-2" exact="infection" post="and they were the ages of 18 and 60â€‰years"/>
 <result pre="tested negative for SARS-CoV-2 and were tested negative for other" exact="respiratory" post="viruses, also for hepatitis B virus, hepatitis C virus,"/>
 <result pre="and were tested negative for other respiratory viruses, also for" exact="hepatitis" post="B virus, hepatitis C virus, syphilis, and HIV at"/>
 <result pre="negative for other respiratory viruses, also for hepatitis B virus," exact="hepatitis C" post="virus, syphilis, and HIV at the time of blood"/>
 <result pre="Plasma Patient 1 2 3 4 5 Sex Male Male" exact="Female" post="Female Male Age, y 70s 60s 50s 30s 60s"/>
 <result pre="Patient 1 2 3 4 5 Sex Male Male Female" exact="Female" post="Male Age, y 70s 60s 50s 30s 60s Weight,"/>
 <result pre="85 60 41.5 87 Smoking No No No No No" exact="Blood" post="type B B B A B Coexisting chronic disease"/>
 <result pre="60 41.5 87 Smoking No No No No No Blood" exact="type B" post="B B A B Coexisting chronic disease None Hypertension;"/>
 <result pre="No No Blood type B B B A B Coexisting" exact="chronic" post="disease None Hypertension; mitral Insufficiency None None None Disease"/>
 <result pre="No Blood type B B B A B Coexisting chronic" exact="disease" post="None Hypertension; mitral Insufficiency None None None Disease presentation"/>
 <result pre="B B A B Coexisting chronic disease None Hypertension; mitral" exact="Insufficiency" post="None None None Disease presentation and course â€ƒEstimated incubation"/>
 <result pre="Coexisting chronic disease None Hypertension; mitral Insufficiency None None None" exact="Disease" post="presentation and course â€ƒEstimated incubation period, da 1 7"/>
 <result pre="20 19 20 â€ƒComplications prior to plasma transfusion Bacterial pneumonia;" exact="Severe" post="ARDS; MODS Bacterial pneumonia; Fungal pneumonia; severe ARDS; myocardial"/>
 <result pre="to plasma transfusion Bacterial pneumonia; Severe ARDS; MODS Bacterial pneumonia;" exact="Fungal" post="pneumonia; severe ARDS; myocardial damage severe ARDS severe ARDS"/>
 <result pre="myocardial damage severe ARDS severe ARDS severe ARDS â€ƒMost severe" exact="disease" post="classification Critical Critical Critical Critical Critical Treatments â€ƒSteroids Methylprednisolone"/>
 <result pre="results are indicated in Table 7. Table 7 Comparison of" exact="Viral" post="Load, Clinical Indexes, and Laboratory Results Before and After"/>
 <result pre="in plasma from recovering COVID-19-infected cases can help stop the" exact="infection" post="in people who are still sick or not. Dr."/>
 <result pre="exploring strategies for SARA-CoV-2 vaccine development [111]. Chinese Centre for" exact="Disease" post="Control and Prevention (CDC) is working on an inactivated"/>
 <result pre="whole virus vaccines [106]. the University of Queensland is synthesizing" exact="viral" post="surface proteins, under funding from the Coalition for Epidemic"/>
 <result pre="synthesizing viral surface proteins, under funding from the Coalition for" exact="Epidemic" post="Preparedness (CEPI), in the purpose of presenting them more"/>
 <result pre="body is misled to generate antibodies by adding genes of" exact="viral" post="proteins. The process is now in the preclinical state,"/>
 <result pre="pang et al. [111] GeoVaxâ€&quot;BravoVax are working on a â€œModified" exact="Vaccinia" post="Ankaraâ€&quot;Virus-Like Particles (MVA-VLP) vaccine platformâ€�. Nucleic Acid Vaccines: immunizing"/>
 <result pre="at the end of this month in Germany (https://www.nytimes.com/2020/04/08/health/coronavirus-vaccines.html). Monoclonal" exact="Antibody" post="Passive antibody therapy can be a helpful technique to"/>
 <result pre="on the foreign virus particle. So they can decrease the" exact="disease" post="severity and also the virus replication rate which could"/>
 <result pre="recombinant monoclonal antibodies could be tested against SARS-CoV-2 [120]. CoV" exact="infections" post="begin with the interaction of the receptor-binding domain located"/>
 <result pre="which is difficult to achieve in clinical application in a" exact="short" post="time. Future of Treatments for SARS-CoV-2 Infections As SARS-CoV-2"/>
 <result pre="application in a short time. Future of Treatments for SARS-CoV-2" exact="Infections" post="As SARS-CoV-2 is similar to SARS-CoV, applying different kinds"/>
 <result pre="were effective for other SARS-CoV, may be helpful for this" exact="infection" post="too. Results of covalent plasma and under development vaccines"/>
 <result pre="camostat mesylate which is a nonspecific protease inhibitor can inhibit" exact="infection" post="and disease with a Pseudovirus bearing the S protein"/>
 <result pre="which is a nonspecific protease inhibitor can inhibit infection and" exact="disease" post="with a Pseudovirus bearing the S protein of SARS-CoV-2."/>
 <result pre="indicated to partially reduce SARS-CoV-2 growth [123]. In a normal" exact="adult" post="human lung, ACE2 is expressed firstly in alveolar epithelial"/>
 <result pre="normal adult human lung, ACE2 is expressed firstly in alveolar" exact="epithelial" post="type II cells and it can play a role"/>
 <result pre="adult human lung, ACE2 is expressed firstly in alveolar epithelial" exact="type II" post="cells and it can play a role as a"/>
 <result pre="II cells and it can play a role as a" exact="viral" post="source [124]. These cells produce surfactant and it decreases"/>
 <result pre="that ACE2 is expressed in different extrapulmonary tissues like heart," exact="blood vessels," post="kidney, and intestine [126â€&quot;130]. The ACE2 tissue distribution in"/>
 <result pre="showing that hrsACE2 can block the first entry of SARS-CoV-2" exact="infections" post="in host cells. As such, we cannot make any"/>
 <result pre="to the effect of hrsACE2 in later stages of the" exact="disease" post="process (https://www.cell.com/pb-assets/products/coronavirus/CELL_CELL-D-20-00739.pdf). We recommend that further studies are needed"/>
 <result pre="to clarify the effect of hrsACE2 at later stages of" exact="infection" post="in vitro and in vivo. Finally the Best Way"/>
 <result pre="efficient drugs and therapeutic strategies to reduce mortality of coronavirus" exact="disease" post="but among all the ways for treathing COVID-19, prevention"/>
 <result pre="PHEIC Public Health Emergency of International Concern MERS Middle East" exact="Respiratory" post="Syndrome SARS Severe Acute Respiratory Syndrome RT-PCR Reverse-transcription Polymerase"/>
 <result pre="Public Health Emergency of International Concern MERS Middle East Respiratory" exact="Syndrome" post="SARS Severe Acute Respiratory Syndrome RT-PCR Reverse-transcription Polymerase Chain"/>
 <result pre="Emergency of International Concern MERS Middle East Respiratory Syndrome SARS" exact="Severe" post="Acute Respiratory Syndrome RT-PCR Reverse-transcription Polymerase Chain Reaction rRT-PCR"/>
 <result pre="of International Concern MERS Middle East Respiratory Syndrome SARS Severe" exact="Acute" post="Respiratory Syndrome RT-PCR Reverse-transcription Polymerase Chain Reaction rRT-PCR Reverse"/>
 <result pre="International Concern MERS Middle East Respiratory Syndrome SARS Severe Acute" exact="Respiratory" post="Syndrome RT-PCR Reverse-transcription Polymerase Chain Reaction rRT-PCR Reverse Real-Time"/>
 <result pre="Concern MERS Middle East Respiratory Syndrome SARS Severe Acute Respiratory" exact="Syndrome" post="RT-PCR Reverse-transcription Polymerase Chain Reaction rRT-PCR Reverse Real-Time PCR"/>
 <result pre="Acid WHO World Health Organization CQ Chloroquine MOI Multiplicity of" exact="Infection" post="EC50 half-maximal Effective Concentration CC50 Half-Cytotoxic Concentration HCQ Hydroxychloroquine"/>
 <result pre="half-maximal Effective Concentration CC50 Half-Cytotoxic Concentration HCQ Hydroxychloroquine HIV Human" exact="Immunodeficiency" post="Viruses RAAS Renin-Angiotensin-Aldosterone System AT1R Angiotensin Receptor 1 ACE"/>
 <result pre="Endopeptidase C30 CYP3A Cytochrome P4503A IFN-Î²1b Interferon Beta-1b CRP C-reactive" exact="Protein" post="LDH Lactate Dehydrogenase CDC Chinese Centre for Disease Control"/>
 <result pre="CRP C-reactive Protein LDH Lactate Dehydrogenase CDC Chinese Centre for" exact="Disease" post="Control and Prevention CEPI Coalition for Epidemic Preparedness S-Trimer"/>
 <result pre="Chinese Centre for Disease Control and Prevention CEPI Coalition for" exact="Epidemic" post="Preparedness S-Trimer Subunit-trimer Vaccine RBD Receptor-binding Domain ACE2 Angiotensin-converting"/>
 <result pre="HD. Discovery of a novel coronavirus associated with the recent" exact="pneumonia" post="outbreak in humans and its potential bat origin. BioRxiv."/>
 <result pre="Der WerfSBrodtHRBeckerSRabenauHPanningMKolesnikovaLFouchierRABergerAIdentification of a novel coronavirus in patients with severe" exact="acute" post="respiratory syndromeN Engl J Med2003348201967197610.1056/NEJMoa03074712690091 6.ZakiAMVan BoheemenSBestebroerTMOsterhausADFouchierRAIsolation of a"/>
 <result pre="WerfSBrodtHRBeckerSRabenauHPanningMKolesnikovaLFouchierRABergerAIdentification of a novel coronavirus in patients with severe acute" exact="respiratory" post="syndromeN Engl J Med2003348201967197610.1056/NEJMoa03074712690091 6.ZakiAMVan BoheemenSBestebroerTMOsterhausADFouchierRAIsolation of a novel"/>
 <result pre="6.ZakiAMVan BoheemenSBestebroerTMOsterhausADFouchierRAIsolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi ArabiaN Engl J Med2012367191814182010.1056/NEJMoa121172123075143 7.Huang C, Wang"/>
 <result pre="recombination, and pathogenesis of coronavirusesTrends Microbiol201624649050227012512 13.Cavanagh D. Coronavirus avian" exact="infectious" post="bronchitis virus. Vet Res. 2007;38(2):281â€&quot;297.doi:http:// 10.1051/vetres:2006055. 14.IsmailMMTangYSaifYMPathogenicity of turkey"/>
 <result pre="and pathogenesis of coronavirusesTrends Microbiol201624649050227012512 13.Cavanagh D. Coronavirus avian infectious" exact="bronchitis" post="virus. Vet Res. 2007;38(2):281â€&quot;297.doi:http:// 10.1051/vetres:2006055. 14.IsmailMMTangYSaifYMPathogenicity of turkey coronavirus"/>
 <result pre="of turkey coronavirus in turkeys and chickensAvian Dis200347351552214562877 15.ZhouPFanHLanTYangXLShiWFZhangWZhuYZhangYWXieQMManiSZhengXSFatal swine" exact="acute" post="diarrhoea syndrome caused by an HKU2-related coronavirus of bat"/>
 <result pre="coronavirus in turkeys and chickensAvian Dis200347351552214562877 15.ZhouPFanHLanTYangXLShiWFZhangWZhuYZhangYWXieQMManiSZhengXSFatal swine acute diarrhoea" exact="syndrome" post="caused by an HKU2-related coronavirus of bat originNature2018556770025525829618817 16.Corman"/>
 <result pre="Jan 1 (Vol. 100, pp. 163â€&quot;188). Academic Press. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112090/. 17.PeirisJSGuanYYuenKYSevere" exact="acute" post="respiratory syndromeNat Med20041012S88S9715577937 18.Chan-YeungMXuRHSARS: epidemiologyRespirology20038S91415018127 19.LeeJChowellGJungEA dynamic compartmental model"/>
 <result pre="1 (Vol. 100, pp. 163â€&quot;188). Academic Press. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112090/. 17.PeirisJSGuanYYuenKYSevere acute" exact="respiratory" post="syndromeNat Med20041012S88S9715577937 18.Chan-YeungMXuRHSARS: epidemiologyRespirology20038S91415018127 19.LeeJChowellGJungEA dynamic compartmental model for"/>
 <result pre="18.Chan-YeungMXuRHSARS: epidemiologyRespirology20038S91415018127 19.LeeJChowellGJungEA dynamic compartmental model for the Middle East" exact="respiratory" post="syndrome outbreak in the Republic of Korea: a retrospective"/>
 <result pre="epidemiologyRespirology20038S91415018127 19.LeeJChowellGJungEA dynamic compartmental model for the Middle East respiratory" exact="syndrome" post="outbreak in the Republic of Korea: a retrospective analysis"/>
 <result pre="Lu R, Niu P. A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019. New Engl J Med. 2020 Jan"/>
 <result pre="detection using recombination proteinsPLoS Biol200647e20416756388 25.[cited 2020 march 27]; Coronavirus" exact="disease" post="2019 (COVID-19)Situation Report âˆ’67.Available from: https://www.who.int/#. 26.Xiang YT, Yang"/>
 <result pre="2019 [cited 2020 march 28]; Available from: https://www.cdc.gov/features/rhinoviruses/index.html. 31.DavisJMMurphyEAMcClellanJLCarmichaelMDGangemiJDQuercetin reduces" exact="susceptibility to" post="influenza infection following stressful exerciseAm J Physiol Regul Integ"/>
 <result pre="march 28]; Available from: https://www.cdc.gov/features/rhinoviruses/index.html. 31.DavisJMMurphyEAMcClellanJLCarmichaelMDGangemiJDQuercetin reduces susceptibility to influenza" exact="infection" post="following stressful exerciseAm J Physiol Regul Integ Comp Physiol20082952R505R509"/>
 <result pre="the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected" exact="pneumonia" post="(standard version)Military Med Res2020714 34.Gao J, Tian Z, Yang"/>
 <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studies. Bioscience Trends. 2020. 10.5582/bst.2020.01047. 35.Luo H,"/>
 <result pre="Can Chinese medicine be used for prevention of corona virus" exact="disease" post="2019 (COVID-19)? A review of historical classics, research evidence"/>
 <result pre="an herbal formula by hospital care workers during the severe" exact="acute" post="respiratory syndrome epidemic in Hong Kong to prevent severe"/>
 <result pre="herbal formula by hospital care workers during the severe acute" exact="respiratory" post="syndrome epidemic in Hong Kong to prevent severe acute"/>
 <result pre="formula by hospital care workers during the severe acute respiratory" exact="syndrome" post="epidemic in Hong Kong to prevent severe acute respiratory"/>
 <result pre="acute respiratory syndrome epidemic in Hong Kong to prevent severe" exact="acute" post="respiratory syndrome transmission, relieve influenza-related symptoms, and improve quality"/>
 <result pre="respiratory syndrome epidemic in Hong Kong to prevent severe acute" exact="respiratory" post="syndrome transmission, relieve influenza-related symptoms, and improve quality of"/>
 <result pre="syndrome epidemic in Hong Kong to prevent severe acute respiratory" exact="syndrome" post="transmission, relieve influenza-related symptoms, and improve quality of life:"/>
 <result pre="RNA virusesAntiviral Res2018153859429524445 43.FurutaYKomenoTNakamuraTFavipiravir (T-705), a broad spectrum inhibitor of" exact="viral" post="RNA polymeraseProceed Japan Acad B2017937449463 44.Cai Q, Yang M,"/>
 <result pre="2006;6(2):67â€&quot;69.doi: 10.1016/S1473-3099(06)70361-9. 47.VincentMJBergeronEBenjannetSEricksonBRRollinPEKsiazekTGSeidahNGNicholSTChloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol J2005211015631631 48.KwiekJJHaysteadTARudolphJKinetic mechanism of quinone oxidoreductase 2"/>
 <result pre="193â€&quot;198). Springer, Boston, MA.doi: 10.1007/978-1-4615-1325-4_31. 51.KonoMTatsumiKImaiAMSaitoKKuriyamaTShirasawaHInhibition of human coronavirus 229E" exact="infection" post="in human epithelial lung cells (L132) by chloroquine: involvement"/>
 <result pre="MA.doi: 10.1007/978-1-4615-1325-4_31. 51.KonoMTatsumiKImaiAMSaitoKKuriyamaTShirasawaHInhibition of human coronavirus 229E infection in human" exact="epithelial" post="lung cells (L132) by chloroquine: involvement of p38 MAPK"/>
 <result pre="FDA-approved compound library identifies four small-molecule inhibitors of Middle East" exact="respiratory" post="syndrome coronavirus replication in cell cultureAntimicrob Agents Chemother20145884875488410.1128/AAC.03011-1424841269 53.Ruiz-Irastorza"/>
 <result pre="compound library identifies four small-molecule inhibitors of Middle East respiratory" exact="syndrome" post="coronavirus replication in cell cultureAntimicrob Agents Chemother20145884875488410.1128/AAC.03011-1424841269 53.Ruiz-Irastorza G,"/>
 <result pre="Khamashta MA. Clinical efficacy and side effects of antimalarials in" exact="systemic" post="lupus erythematosus: a systematic review. Ann Rheum Dis. 2010"/>
 <result pre="MA. Clinical efficacy and side effects of antimalarials in systemic" exact="lupus" post="erythematosus: a systematic review. Ann Rheum Dis. 2010 Jan"/>
 <result pre="action of hydroxychloroquine as an antirheumatic drug. In Seminars in" exact="arthritis" post="and rheumatism 1993(Vol. 23, No. 2, pp. 82â€&quot;91). WB"/>
 <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020"/>
 <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Mar"/>
 <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Mar 9."/>
 <result pre="analog GS-441524 for treatment of cats with naturally occurring feline" exact="infectious" post="peritonitisJ Feline Med Surg201921427128130755068 58.Sheahan TP, Sims AC, Graham"/>
 <result pre="combination therapy with lopinavir/ritonavir, ribavirin and interferon-Î± for Middle East" exact="respiratory" post="syndromeAntivir Ther20162145545910.3851/IMP300226492219 65.ZeinalianMSalari-JaziAJannesariAKhanahmadHA potential protective role of losartan against"/>
 <result pre="renin-angiotensin system blockersHypertension20207561382138532208987 68.Camm NJ, Sherie S. Understanding Mechanism of" exact="Infection" post="and outlining definitive therapy for Corona Virus (COVID-19).doi: 10.9790/3008-1502026065."/>
 <result pre="Zheng X, Huang M, Luo L, Liang J, Wen X." exact="Viral" post="invasion and type i interferon response characterize the immunophenotypes"/>
 <result pre="the binding effect of ritonavir, lopinavir and darunavir to severe" exact="acute" post="respiratory syndrome coronavirus 2 proteases. bioRxiv. 2020 Jan 1."/>
 <result pre="binding effect of ritonavir, lopinavir and darunavir to severe acute" exact="respiratory" post="syndrome coronavirus 2 proteases. bioRxiv. 2020 Jan 1. 10.1101/2020.01.31.929695."/>
 <result pre="effect of ritonavir, lopinavir and darunavir to severe acute respiratory" exact="syndrome" post="coronavirus 2 proteases. bioRxiv. 2020 Jan 1. 10.1101/2020.01.31.929695. 74.BhatnagarTMurhekarMVSonejaMGuptaNGiriSWigNGangakhedkarRLopinavir/ritonavir"/>
 <result pre="proteases. bioRxiv. 2020 Jan 1. 10.1101/2020.01.31.929695. 74.BhatnagarTMurhekarMVSonejaMGuptaNGiriSWigNGangakhedkarRLopinavir/ritonavir combination therapy amongst" exact="symptomatic" post="coronavirus disease 2019 patients in India: protocol for restricted"/>
 <result pre="2020 Jan 1. 10.1101/2020.01.31.929695. 74.BhatnagarTMurhekarMVSonejaMGuptaNGiriSWigNGangakhedkarRLopinavir/ritonavir combination therapy amongst symptomatic coronavirus" exact="disease" post="2019 patients in India: protocol for restricted public health"/>
 <result pre="and Treatment of COVID-19. Med Hypotheses. 2020:109848. 10.1016/j.mehy.2020.109848. 86.SkalnyAVRinkLAjsuvakovaOPAschnerMGritsenkoVAAlekseenkoSISvistunovAAPetrakisDSpandidosDAAasethJTsatsakisAZinc and" exact="respiratory" post="tract infections: Perspectives for COVID-19Int J Mol Med2020461172632319538 87.DrigginEMadhavanMVBikdeliBChuichTLaracyJBiondi-ZoccaiGBrownTSDer"/>
 <result pre="methylprednisolone treatment in SARS patientsClin Microbiol Infect200410767667815214887 90.LaiSTTreatment of severe" exact="acute" post="respiratory syndromeEur J Clin Microbiol Infect Dis200524958359116172857 91.ChengYWongRSooYOWongWSLeeCKNgMHChanPWongKCLeungCBChengGUse of"/>
 <result pre="treatment in SARS patientsClin Microbiol Infect200410767667815214887 90.LaiSTTreatment of severe acute" exact="respiratory" post="syndromeEur J Clin Microbiol Infect Dis200524958359116172857 91.ChengYWongRSooYOWongWSLeeCKNgMHChanPWongKCLeungCBChengGUse of convalescent"/>
 <result pre="blood or plasma collected from patients recovered from Ebola virus" exact="disease" post="for transfusion, as an empirical treatment during outbreaks: interim"/>
 <result pre="effects of convalescent plasma therapy for patients with Middle East" exact="respiratory" post="syndrome coronavirus infection: a study protocolSpringerplus2015411825674489 94.HungIFcollab: To KKLeeCKLeeKLChanKYanWWLiuRWattCLChanWMLaiKYKooCKConvalescent"/>
 <result pre="of convalescent plasma therapy for patients with Middle East respiratory" exact="syndrome" post="coronavirus infection: a study protocolSpringerplus2015411825674489 94.HungIFcollab: To KKLeeCKLeeKLChanKYanWWLiuRWattCLChanWMLaiKYKooCKConvalescent plasma"/>
 <result pre="HIV-1 in vivoScience.201635262881001100410.1126/science.aaf127927199430 97.World Health Organization %J Emergencies preparedness, r.," exact="Disease" post="outbreak news, World Health Organization, Pneumonia of unknown causeâ€&quot;China."/>
 <result pre="%J Emergencies preparedness, r., Disease outbreak news, World Health Organization," exact="Pneumonia" post="of unknown causeâ€&quot;China. 2020. 98.LukeTCKilbaneEMJacksonJLHoffmanSLMeta-analysis: convalescent blood products for"/>
 <result pre="step in understanding SARS pathogenesisJ Pathol2004203263163715141377 128.DingYHeLIZhangQHuangZCheXHouJWangHShenHQiuLLiZGengJOrgan distribution of severe" exact="acute" post="respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients:"/>
 <result pre="in understanding SARS pathogenesisJ Pathol2004203263163715141377 128.DingYHeLIZhangQHuangZCheXHouJWangHShenHQiuLLiZGengJOrgan distribution of severe acute" exact="respiratory" post="syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications"/>
 <result pre="understanding SARS pathogenesisJ Pathol2004203263163715141377 128.DingYHeLIZhangQHuangZCheXHouJWangHShenHQiuLLiZGengJOrgan distribution of severe acute respiratory" exact="syndrome" post="(SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for"/>
 <result pre="and virus transmission pathwaysJ Pathol2004203262263015141376 129.DanilczykUPenningerJMAngiotensin-converting enzyme II in the" exact="heart" post="and the kidneyCirc Res200698446347116514079 130.CrackowerMASaraoROuditGYYagilCKozieradzkiIScangaSEOliveira-dos-SantosAJda CostaJZhangLPeiYScholeyJAngiotensin-converting enzyme 2 is"/>
 <result pre="Res200698446347116514079 130.CrackowerMASaraoROuditGYYagilCKozieradzkiIScangaSEOliveira-dos-SantosAJda CostaJZhangLPeiYScholeyJAngiotensin-converting enzyme 2 is an essential regulator of" exact="heart" post="functionNature2002417689182282812075344 131.Guan WJ, Ni ZY, Hu Y, Liang WH,"/>
 <result pre="Lei CL, Hui DS, Du B. Clinical characteristics of coronavirus" exact="disease" post="2019 in China. New Engl J Med. 2020;382(18):1708â€&quot;1720.doi: DOI:"/>
</results>
